Literature DB >> 18419469

Vaccines to prevent systemic mycoses: holy grails meet translational realities.

John N Galgiani1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18419469      PMCID： PMC2763442          DOI： 10.1086/529205

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  27 in total

1.  Immunity to coccidioi-domycosis induced in mice by purified spherule, arthrospore, and mycelial vaccines.

Authors:  H B LEVINE; J M COBB; C E SMITH
Journal:  Trans N Y Acad Sci       Date:  1960-04

2.  Identification of a protective antigen of Coccidioides immitis by expression library immunization.

Authors:  F Douglas Ivey; D Mitchell Magee; Melanie D Woitaske; Stephen Albert Johnston; Rebecca A Cox
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

3.  Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Lin Lin; Valentina Avanesian; Yue Fu; Peter Lipke; Henry Otoo; Tiffany Ho; John E Edwards
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

4.  The present status of vaccination against coccidioidomycosis in man.

Authors:  D Pappagianis; H B Levine
Journal:  Am J Epidemiol       Date:  1975-07       Impact factor: 4.897

5.  Reinfection with coccidioidomycosis.

Authors:  D Salkin; A Said
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

6.  Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group.

Authors:  D Pappagianis
Journal:  Am Rev Respir Dis       Date:  1993-09

Review 7.  A vaccine against coccidioidomycosis is justified and attainable.

Authors:  G T Cole; J M Xue; C N Okeke; E J Tarcha; V Basrur; R A Schaller; R A Herr; J J Yu; C Y Hung
Journal:  Med Mycol       Date:  2004-06       Impact factor: 4.076

8.  A recombinant beta-1,3-glucanosyltransferase homolog of Coccidioides posadasii protects mice against coccidioidomycosis.

Authors:  Nelson Delgado; Jianmin Xue; Jieh-Juen Yu; Chiung-Yu Hung; Garry T Cole
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

9.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

10.  Cost-effectiveness of a potential vaccine for Coccidioides immitis.

Authors:  A E Barnato; G D Sanders; D K Owens
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883
View more
  8 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

Review 2.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

3.  A Coccidioides posadasii CPS1 Deletion Mutant Is Avirulent and Protects Mice from Lethal Infection.

Authors:  Hema P Narra; Lisa F Shubitz; M Alejandra Mandel; Hien T Trinh; Kurt Griffin; Adam S Buntzman; Jeffrey A Frelinger; John N Galgiani; Marc J Orbach
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

Review 4.  Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Authors:  Chinh Nguyen; Bridget Marie Barker; Susan Hoover; David E Nix; Neil M Ampel; Jeffrey A Frelinger; Marc J Orbach; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  Vaccine-induced cellular immune responses differ from innate responses in susceptible and resistant strains of mice infected with Coccidioides posadasii.

Authors:  Lisa F Shubitz; Sharon M Dial; Robert Perrill; Rachael Casement; John N Galgiani
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

Review 6.  The Rise of Coccidioides: Forces Against the Dust Devil Unleashed.

Authors:  Marley C Caballero Van Dyke; George R Thompson; John N Galgiani; Bridget M Barker
Journal:  Front Immunol       Date:  2019-09-11       Impact factor: 7.561

7.  Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis.

Authors:  Amy J Grizzle; Leslie Wilson; David E Nix; John N Galgiani
Journal:  Open Forum Infect Dis       Date:  2020-12-28       Impact factor: 3.835

Review 8.  Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials.

Authors:  John N Galgiani; Lisa F Shubitz; Marc J Orbach; M Alejandra Mandel; Daniel A Powell; Bruce S Klein; Edward J Robb; Mana Ohkura; Devin J Seka; Thomas M Tomasiak; Thomas P Monath
Journal:  J Fungi (Basel)       Date:  2022-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.